Option Care Health Inc

Schneider Electric SE agreed to acquire U.S.-based engineering software developer PTC Inc. for $22.6 billion, or €20.1 billion, paying $205 per share in an all-cash deal. The transaction was among a string of major deals reported across sectors this week. Viatris said it will acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, while CD&R and McKesson agreed to acquire Option Care Health for $32.05 per share, valuing it at approximately $5.8 billion including debt, sending its shares up 34% in early trading Tuesday. Energy Transfer agreed to acquire Vaquero Midstream in a $2.625 billion deal consisting of $1.95 billion in cash and about 33.3 million newly issued Energy Transfer common units, and Cenovus Energy agreed to acquire Athabasca Oil in a cash-and-stock deal valued at about C$5.7 billion, a 14% premium to Athabasca's 20-day volume-weighted average trading price. Canadian utilities Emera and Canadian Utilities agreed to an all-stock merger worth C$14.3 billion, or US$10 billion, creating a combined company with a C$72 billion enterprise value and a regulated rate base of C$45 billion serving roughly 6 million customers. Separately, TKO LLC proposed to acquire Service Properties Trust's entire hospitality portfolio for $2.0 billion, and CCC Intelligent Solutions soared 13% in after-hours trading on a report that GTCR and Elliott Investment Management are in advanced discussions to purchase the car-insurance software firm.

McKesson Corporation is partnering with private equity firm Clayton, Dubilier & Rice to acquire Option Care Health, Inc. for $5.8 billion including debt, taking the infusion-services provider private at $32.05 per share, a 37% premium to its previous closing price. Under the structure announced on October 6, CD&R will own 51% of the business while McKesson will hold 49% and retain the right to acquire its partner's stake in the future. The deal extends McKesson's push beyond traditional pharmaceutical distribution into higher-value specialty services, following its previously announced $2.25 billion agreement to acquire Precision Medicine Group. Option Care, which served more than 315,000 patients last year through home-based services and 184 care centers, reported second-quarter revenue up 1.9% to $1.44 billion and adjusted EBITDA up 3% to $117.5 million, and withdrew its 2026 guidance of $5.675 billion to $5.775 billion in revenue following the announcement. Analysts at Barrington and William Blair both downgraded Option Care to Market Perform, calling the $32.05-per-share offer attractive and a competing bid unlikely, while Morgan Stanley maintained an Overweight rating and a $977 price target on McKesson.

Option Care Health has agreed to a US$5.8 billion buyout from McKesson and Clayton Dubilier & Rice at US$32.05 per share in cash, sending the stock up 37.5% over the past week. The shares now trade near the deal level at about 22.2 times earnings, below the broader healthcare sector at roughly 24.7 times and the peer group average near 43.7 times. Community views on Option Care Health split between a bull case calling the stock 19% undervalued on home-infusion growth and a bear case calling it 9% overvalued after the company cut its 2026 revenue guidance to a range of US$5.675 billion to US$5.775 billion, citing a roughly 600 basis point revenue growth headwind from chronic inflammatory disease therapies.

Option Care Health has agreed to be acquired by CD&R and McKesson for $32.05 per share in cash, sending OPCH shares 32.7% higher to close at $31. The offer represents a roughly 37% premium to Option Care Health's October 5, 2026 closing price and values the company at approximately $5.8 billion in enterprise value. The deal underscores the strategic appeal of Option Care's home and alternate-site infusion care platform and reduces near-term uncertainty around its standalone outlook. Ahead of its upcoming report, Option Care is expected to post quarterly earnings of $0.48 per share, up 6.7% year over year, on revenues of $1.47 billion, up 2.4% from the year-ago quarter, with the consensus EPS estimate unchanged over the last 30 days. The stock currently carries a Zacks Rank #2 (Buy).

Google and Constellation Energy announced a 20-year deal to bring 890 MW of new nuclear capacity onto the PJM grid in Illinois, Pennsylvania and New Jersey, with Constellation spending more than $4.3 billion on the build-out. The deal follows Amazon's similar agreement with Constellation, as surging electricity demand from AI revives interest in nuclear power. Separately, Option Care Health shares jumped after the Financial Times reported that McKesson and private equity firm Clayton Dubilier & Rice are closing in on a deal to buy the medical infusion provider for $32.50 a share, or a total enterprise value of about $5.8 billion including debt, representing a 37% premium to the prior close. Under the deal, CD&R would hold a 51% majority interest and McKesson would invest $1.4 billion for a 49% stake, with Option Care remaining a separate company led by its own management. SpaceX shares were the most actively traded in the premarket as NASA nears announcing a bulk purchase of rocket launches to fuel its $30 billion drive to build a permanent base on the moon.

Google announced a major long-term power agreement with Constellation Energy, under which it will buy power tied to 890 megawatts of new nuclear capacity alongside a separate 2,700-megawatt supply agreement, supporting more than $4.3 billion in new Constellation investment. Constellation Energy shares jumped more than 6% premarket on the news, while Alphabet rose about 0.5%. Separately, Option Care Health shares surged more than 20% following a Financial Times report that McKesson and private equity firm Clayton Dubilier & Rice are in advanced talks to jointly acquire the infusion services provider in a transaction valued at more than $5 billion; McKesson stock is up 1.5%. Berkshire Hathaway disclosed in a regulatory filing that it purchased about 2.4 million shares of Lennar, sending Lennar up 1.5%. NeoGenomics rose 5% after announcing that current President and COO Warren Stone will take the helm from Tony Cook in January 2027, and reporting preliminary third-quarter total revenue of $209 million, topping the $205.9 million consensus estimate, per FactSet. Advanced Micro Devices rose nearly 2% after Citi raised its price target to $800, citing greater CPU demand driven by Meta's Muse AI agent, while Procter & Gamble rose 1.2% on an Evercore ISI upgrade to outperform and a price target increase to $166 from $161, and Corteva rose nearly 3% after JPMorgan upgraded the stock to overweight from neutral with a $19 price target.

Option Care Health reported second quarter 2026 net revenue of $1.44 billion, a 1.9% increase year over year, driven by high-single-digit organic growth in its acute therapy portfolio. Adjusted EBITDA rose 3% to $117.5 million, and adjusted EPS increased 9.8% to $0.45, including a $0.03 benefit from share repurchases. The company maintained its full-year revenue guidance of $5.675 billion to $5.775 billion but narrowed its adjusted EBITDA range to $480 million to $495 million and adjusted EPS to $1.85 to $1.92. Management cited stabilization in the chronic inflammatory disease patient census, sequential growth in IG neuro and rare and orphan portfolios, and the addition of five new ambulatory infusion clinics. Option Care Health repurchased $150 million of stock in the quarter, leaving $525 million under its current authorization, and ended with a net debt leverage ratio of 2.1 times.

Option Care Health reported second-quarter revenue of $1.44 billion, exceeding analyst estimates of $1.42 billion and marking a 1.9% year-on-year increase. Adjusted earnings per share came in at $0.45, a 5.4% beat over the consensus of $0.43, while adjusted EBITDA of $117.5 million also topped expectations. The company reconfirmed its full-year revenue guidance at $5.73 billion and slightly raised its adjusted EPS outlook to $1.89 at the midpoint. Management attributed the outperformance to high-single-digit organic growth in the acute therapy portfolio and stabilization in the chronic inflammatory disease segment, supported by cost controls and technology investments.

Companies across healthcare services, insurance, and cloud-managed services are deploying AI-driven automation to protect margins. Travelers disclosed that more than half of all claims are eligible for straight-through processing, with customers adopting it about two-thirds of the time, and framed efficiency gains as something that can fall to the bottom line through expense ratio flexibility. Concentrix reported its proprietary AI platform is running at an approximately $60 million run-rate on total spend of a little over $50 million, with expected margin improvement as it works through overcapacity and duplicate costs. Option Care Health is using AI to streamline patient onboarding workflows, aiming to scale patient census without proportional labor-force growth. DarioHealth expects its proprietary AI engine DarioIQ to increase recurring revenue from existing customers by 10 to 15 percent, with ROI tied to higher engagement and lifetime value without proportional acquisition cost growth.

Option Care Health has been ranked No. 15 on TIME's World's Most Impactful Companies 2026 list, highlighting its home and alternate-site infusion care model. The company describes itself as the nation's largest independent provider in that category, with more than 8,000 team members and over 5,000 clinicians serving patients in all 50 states. Analysts' average target implies roughly 30.5% upside for the stock. The recognition underscores the site-of-care substitution theme, where moving infusion services from hospitals to patient homes or alternate sites may offer lower costs while requiring clinical coordination, scale, and reliability.

A bullish thesis on Option Care Health, Inc. argues the stock offers an asymmetric risk-reward opportunity following a roughly 30 percent share price decline driven by Stelara biosimilar disruption. The company is the largest independent provider of home and alternate-site infusion services in the United States, with quarterly revenues in the $1.3 to $1.4 billion range and forward EBITDA margin guidance improving toward about 8.5 percent. The thesis contends that additional biosimilar or self-administration substitution risk is limited until late 2027 to 2028, and the valuation already reflects pessimism with a forward P/E near 11 times and EV/EBITDA around 10 times. Upside catalysts include insider buying, pipeline expansion into neurology, oncology, and rare disease infusibles, and secular tailwinds from the shift to home care, with a base case implying 10 to 35 percent upside and a bull case implying 35 to 50 percent upside over the next one to three quarters.